IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

被引：0
|
作者：
Stathis, Anastasios
Gregorini, Anna
Gressin, Remy
Orsucci, Lorella
Perrot, Aurore
Tani, Monica
Coiffier, Bertrand
Musuraca, Gerardo
Guieze, Romain
Marino, Dario
Gini, Guido
Ferrari, Angela
Gyan, Emmanuel
Morschhauser, Franck
Palombi, Francesca
Cavallo, Federica
Le Gouill, Steven
Tilly, Herve
Salvi, Flavia
Conconi, Annarita
Cabras, Maria Giuseppina
Capochiani, Enrico
Califano, Catello
Molinari, Anna Lia
Pulsoni, Alessandro
Ielmini, Nicoletta
Luminari, Stefano
Cavalli, Franco
Zucca, Emanuele
Thieblemont, Catherine
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1506
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A PHASE II STUDY OF RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)
    Raderer, M.
    Kiesewetter, B.
    Willenbacher, W.
    Neumeister, P.
    Fridrik, M.
    Greil, R.
    HAEMATOLOGICA, 2014, 99 : 226 - 226
  • [2] AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)
    Kiesewetter, Barbara
    Greil, Richard
    Willenbacher, Wolfgang
    Neumeister, Peter
    Fridrik, Michael A.
    Markus, Raderer
    BLOOD, 2015, 126 (23)
  • [3] A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)
    Kiesewetter, Barbara
    Troch, Marlene
    Dolak, Werner
    Muellauer, Leonhard
    Lukas, Julius
    Zielinski, Christoph C.
    Raderer, Markus
    HAEMATOLOGICA, 2013, 98 (03) : 353 - 356
  • [4] A PHASE II STUDY OF LENALIDOMIDE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA)
    Kiesewetter, B.
    Troch, M.
    Dolak, W.
    Muellauer, L.
    Lukas, J.
    Zielinski, C.
    Raderer, M.
    HAEMATOLOGICA, 2012, 97 : 326 - 326
  • [5] Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie
    Troch, Marlene
    Kiesewetter, Barbara
    Willenbacher, Wolfgang
    Willenbacher, Ella
    Zebisch, Armin
    Linkesch, Werner
    Fridrik, Michael
    Muellauer, Leonhard
    Greil, Richard
    Raderer, Markus
    HAEMATOLOGICA, 2013, 98 (02) : 264 - 268
  • [6] Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).
    Zucca, Emanuele
    Conconi, Annarita
    Martelli, Maurizio
    Thieblemont, Catherine
    Johnson, Peter
    Lopez Guillermo, Armando
    Bouabdallah, Reda
    Tucci, Alessandra
    Vitolo, Umberto
    Coiffier, Bertrand
    Devizzi, Liliana
    Jardin, Fabrice
    Sebban, Catherine
    Pinotti, Graziella
    Morschhauser, Franck
    Pettengell, Ruth
    Bosly, Andre
    Montserrat, Emilio
    Bellei, Monica
    Pileri, Stefano A.
    Copie-Bergman, Christiane
    Campo, Elias
    Jack, Andrew
    Mazzucchelli, Luca
    Floriani, Irene
    Garavaglia, Daniela
    Torri, Valter
    Cavalli, Franco
    Martinelli, Giovanni
    BLOOD, 2009, 114 (22) : 1514 - 1515
  • [7] RITUXIMAB PLUS SUBCUTANEOUS CLADRIBINE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA ASSOCIATED TISSUE (MALT-LYMPHOMA): A PHASE II STUDY BY THE AGMT (ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE)
    Troch, M.
    Kiesewetter, B.
    Willenbacher, W.
    Willenbacher, E.
    Zebisch, A.
    Linkesch, W.
    Fridrik, M. A.
    Muellauer, L.
    Greil, R.
    Raderer, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 352 - 352
  • [8] IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
    Stathis, Anastasios
    Pirosa, Maria Cristina
    Orsucci, Lorella
    Feugier, Pierre
    Tani, Monica
    Ghesquieres, Herve
    Musuraca, Gerardo
    Rossi, Francesca Gaia
    Merli, Francesco
    Guieze, Romain
    Gyan, Emmanuel
    Gini, Guido
    Marino, Dario
    Gressin, Remy
    Morschhauser, Franck
    Cavallo, Federica
    Palombi, Francesca
    Conconi, Annarita
    Tessoulin, Benoit
    Tilly, Herve
    Zanni, Manuela
    Cabras, Maria Giuseppina
    Capochiani, Enrico
    Califano, Catello
    Celli, Melania
    Pulsoni, Alessandro
    Angrilli, Francesco
    Occhini, Ubaldo
    Casasnovas, Rene-Olivier
    Cartron, Guillaume
    Devizzi, Liliana
    Haioun, Corinne
    Liberati, Anna Marina
    Houot, Roch
    Merli, Michele
    Pietrantuono, Giuseppe
    Re, Francesca
    Spina, Michele
    Landi, Francesco
    Cavalli, Franco
    Bertoni, Francesco
    Rossi, Davide
    Ielmini, Nicoletta
    Borgo, Elena
    Luminari, Stefano
    Zucca, Emanuele
    Thieblemont, Catherine
    HAEMATOLOGICA, 2024, 109 (08) : 2564 - 2573
  • [9] FIRST-LINE THERAPY COMBINATION WITH RITUXIMAB AND FLUDARABINE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE TYPE
    Domingo, E.
    Salar, A.
    Muntanola, A.
    Canales, M.
    Pomares, H.
    Servitje, O.
    Gallarrdo, F.
    Montalban, C.
    HAEMATOLOGICA, 2013, 98 : 636 - 636
  • [10] Rituximab-CHOP significantly improve the response of advanced extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Ennishi, Daisuke
    Terui, Yasuhito
    Myojo, Tomohiro
    Mishima, Yuko
    Yokoyama, Masahiro
    Takahashi, Shunji
    Takeuchi, Kengo
    Hatake, Kiyohiko
    BLOOD, 2006, 108 (11) : 261B - 261B
12345